Viridian Therapeutics Initiated with Outperform Rating and 33.24% Upside Potential

William Blair initiates coverage of Viridian Therapeutics (VRDN) with an Outperform recommendation, citing an average one-year price target of $40.54/share, representing a 33.24% increase from its latest closing price. The projected annual revenue is $19MM, a decrease of 73.23%. The put/call ratio of VRDN is 0.26, indicating a bullish outlook.